Literature DB >> 14693705

IL-1 receptor deficiency slows progression to diabetes in the NOD mouse.

Helen E Thomas1, Windy Irawaty, Rima Darwiche, Thomas C Brodnicki, Pere Santamaria, Janette Allison, Thomas W H Kay.   

Abstract

Proinflammatory cytokines are believed to be important in pancreatic beta-cell destruction in the development of type 1 diabetes. They act by upregulation of genes including Fas and inducible nitric oxide synthase (iNOS), which have both been shown to lead to beta-cell death in vitro. We used mice deficient in the interleukin (IL)-1 receptor (IL-1R) to assess the contribution of IL-1 to different models of diabetes. IL-1R-deficient islets were protected from the damaging effects of tumor necrosis factor (TNF) and interferon (IFN)-gamma in vitro, and beta-cell expression of iNOS was reduced, suggesting that IL-1 mediates the induction of iNOS by TNF and IFN-gamma. IL-1 action was not required for induction of class I major histocompatibility complex or Fas by TNF and IFN-gamma. IL-1R-deficient nonobese diabetic (NOD) mice developed diabetes significantly slower than wild-type mice. IL-1R deficiency did not affect diabetes in 8.3 TCR transgenic NOD mice but prolonged the time to diabetes in BDC2.5 TCR transgenic NOD mice. We conclude that IL-1R deficiency slows progression to diabetes in NOD mice but on its own does not prevent diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693705     DOI: 10.2337/diabetes.53.1.113

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  55 in total

Review 1.  Blockade of interleukin 1 in type 1 diabetes mellitus.

Authors:  Thomas Mandrup-Poulsen; Linda Pickersgill; Marc Yves Donath
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

2.  In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model.

Authors:  Boris Calderon; Anish Suri; Emil R Unanue
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

3.  Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes.

Authors:  S Uno; A Imagawa; K Okita; K Sayama; M Moriwaki; H Iwahashi; K Yamagata; S Tamura; Y Matsuzawa; T Hanafusa; J Miyagawa; I Shimomura
Journal:  Diabetologia       Date:  2007-01-13       Impact factor: 10.122

Review 4.  Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 5.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 6.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

Review 7.  Pathogenic mechanisms in type 1 diabetes: the islet is both target and driver of disease.

Authors:  Kate L Graham; Robyn M Sutherland; Stuart I Mannering; Yuxing Zhao; Jonathan Chee; Balasubramanian Krishnamurthy; Helen E Thomas; Andrew M Lew; Thomas W H Kay
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 8.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

Review 9.  Type 1 diabetes: translating mechanistic observations into effective clinical outcomes.

Authors:  Kevan C Herold; Dario A A Vignali; Anne Cooke; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2013-04       Impact factor: 53.106

Review 10.  Islet inflammation: a unifying target for diabetes treatment?

Authors:  Yumi Imai; Anca D Dobrian; Margaret A Morris; Jerry L Nadler
Journal:  Trends Endocrinol Metab       Date:  2013-02-26       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.